7JV-29416-84301
3 vaccinations
5 coded responses
35 check-ins
5 free-text entries
1 call case
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 546 / WI
- Registered
- 2021-01-23
- Relationship
- Self
- Race
- White
- Ethnicity
- Hispanic or Latino
Timeline
-
2021-01-21
Dose 1 — Pfizer-BioNTech
-
2021-01-23
Registered in v-safe
-
2021-01-23
Survey response — days 1–6 daily, dose 1MedDRA: Menstrual disorder — Feeling: Good · Site: PainFree text: Early period( by two weeks)MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-01-24
- 2021-01-25
- 2021-01-26
- 2021-01-27
- 2021-01-28
-
2021-02-04
Survey response — day 14, dose 1MedDRA: Headache — Feeling: FairFree text: HeadacheMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-02-11
Dose 2 — Pfizer-BioNTech
- 2021-02-11
- 2021-02-12
- 2021-02-14
- 2021-02-15
- 2021-02-16
- 2021-02-18
- 2021-02-25
-
2021-03-04
Survey response — day 21, dose 2MedDRA: Rhinorrhoea — Feeling: GoodFree text: Runny noseMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-03-11
- 2021-03-18
- 2021-03-25
- 2021-05-13
- 2021-08-12
-
2021-10-19
Dose 3 — Pfizer-BioNTech
- 2021-10-20
- 2021-10-21
- 2021-10-22
- 2021-10-23
- 2021-10-24
- 2021-10-25
- 2021-10-26
- 2021-11-02
- 2021-11-09
- 2021-11-16
- 2021-11-23
- 2021-12-02
-
2022-01-18
Survey response — 3 months, dose 3MedDRA: Pregnancy — Feeling: GoodFree text: PregnancyMedDRA releases: 2024-11 · check-in free text available
-
2022-04-19
Survey response — 6 months, dose 3MedDRA: Pre-eclampsia — Feeling: Fair · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · HospitalizationFree text: Severe preeclampsiaMedDRA releases: 2024-11 · check-in free text available
-
2022-04-19
Report sent to call center — 6 months, dose 3Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prHospitalization · 1 call case(s)
- 2022-04-20
- 2022-04-25
- 2022-10-19
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-21 | Pfizer-BioNTech | |
| 2 | 2021-02-11 | Pfizer-BioNTech | |
| 3 | 2021-10-19 | Pfizer-BioNTech | No |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2022-04-19 | Unsuccessful |
Free text
Release 2 — days 1–6 daily, dose 1
Systemic reaction (other): Early period( by two weeks)
Release 3 — day 14, dose 1
Symptoms: Headache
Release 5 — day 21, dose 2
Symptoms: Runny nose
Release 10 — 3 months, dose 3
Symptoms: Pregnancy
Release 11 — 6 months, dose 3
Symptoms: Severe preeclampsia
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Headache | ✓ | ✓ | ✓ |
| SD | Pre-eclampsia | · | · | ✓ |
| SD | Pregnancy | · | · | ✓ |
| SD | Rhinorrhoea | ✓ | ✓ | ✓ |
| SRO | Menstrual disorder | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release